Imel Biotherapeutics Inc
Elad Duschak is an accomplished business professional with extensive experience in the healthcare and technology sectors. Currently serving as a Board Member for MEDX Xelerator LP and VLX Ventures, Elad contributes to innovative medical-device incubation and investment initiatives. In addition, Elad holds positions as a Board Observer for Integra Holdings Ltd., Imel Biotherapeutics Inc., and Vensica Medical, and is a member of the Advisory Board for EARLY Labs. As Chairman of The Advisory Board for the UK-Israel HealthTech Forum, Elad fosters partnerships aimed at enhancing healthcare technologies. Previously, Elad served as Chief Business Development Officer at Operose Health and CEO of Ummanu Health. Elad's academic background includes an Executive MBA from The Hebrew University of Jerusalem and a Bachelor’s degree from ISG Institut Supérieur de Gestion.
This person is not in any teams
This person is not in any offices
Imel Biotherapeutics Inc
Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders. It uses a proprietary mitochondrial replaced cells technology, helping physicians to treat multiple patients with mitochondrial genetic or age-related disorders.The company was founded in 2019 and is based in Waltham, Massachusetts.